Description
The Chinese market for cancer intervention is growing at a rapid pace and is mainly catered to by drug and equipment suppliers from outside China. The China market is important for pharmaceutical companies in North America, Europe, and other developed nations which are looking for expansion and large profits in the coming years.
This report analyses the current status of the Chinese market for cancer intervention, outlines the key market drivers and the bases for market segmentation, and studies the trends of this market till 2022.
The Chinese cancer intervention market reached nearly 41.1 billion USD in 2016, and it is estimated to reach a value of 89.3 billion USD by 2022, at a CAGR of 13.8% during the forecast period.
Request for Sample Report @ https://www.wiseguyreports.com/sample-request/2820088-the-chinese-market-for-cancer-intervention
Segmentation:
The Chinese market for cancer intervention includes two major segments, namely cancer diagnosis and detection and cancer treatment. These are further divided into sub-segments based on technology type, product, and end user.
Based on technology, the Chinese cancer intervention market is divided into:
- Antitumor Drugs
- Immunopotentiators
- Immunosuppressors
- Adjuvant Drugs
- Cancer Surgery
- Radiotherapy
- Diagnosis and Detection
According to the product, the market is divided into:
- Drugs used for Cancer Treatment in China
- Adjuvant Drugs
- Cancer Surgery
- Radiotherapy
- Diagnosis and Detection
Depending on end user, the Chinese market for cancer intervention is split into:
- Chinese Lung Cancer Intervention Market
- Chinese Gastric Cancer Intervention Market
- Chinese Liver Cancer Intervention Market
- Chinese Esophageal Cancer Intervention Market
- Chinese Colorectal Cancer Intervention Market
- Chinese Breast Cancer Intervention Market
- Market of Other Cancer Types in China
Regional Analysis:
In this report, China refers to Mainland China, excluding Hongkong, Macau, and Taiwan. Mainland China is divided into a total of 31 province-level regions, which include 22 provinces, four province-level municipalities or cities, and five province-level autonomous regions. Of these, the prominent markets for Chinese cancer intervention include Beijing and Shanghai among others.
Leave a Query @ https://www.wiseguyreports.com/enquiry/2820088-the-chinese-market-for-cancer-intervention
Industry News:
According to the latest updates in this market, in July 2019, a team of research scientists of Chinese Academy of Sciences’ Institute of Zoology in Beijing injected Ivermectin, a commonly available insecticide, into mice with solid malignant tumours and leukaemia. The result was that the cancer cells in the mice immediately succumbed to these drugs. The trial was next carried out on human cells with colorectal and breast cancer, and the experiment had the same positive outcome. The best part of this study is that Ivermectin is different from other pesticides due to its low toxicity to the human body. This drug has also been approved for clinical use by the US Food and Drug Administration and the World Health Organisation and is safe to be directly applied on the skin or taken orally.
In other news of 2019, China has opened up its large market of government hospitals to foreign drug manufacturing companies and has included 17 cancer drugs manufactured by foreign companies in its state basic insurance policies. This is a major opportunity for the Indian pharma companies seeking to expand their base in the Chinese market.
Key Players (Competitor Profiles) :-
Accuragen
Accuray
Annoroad Gene Technology
Astellas
Astrazeneca
Bayer China Ltd.
Beijing Genetron Health Co. Ltd.
Beijing Genomics Institute
Beijing Ipe Center
Beijing Sanvalley Technology Co. Ltd.
Beijing Sciecure Pharmaceutical Co. Ltd.
Beijing Sinomdgene Technology Co. Ltd.
Beijing Solomenbrothers Medical Technology Co. Ltd.
Bristol-Myers Squibb (China) Investment Co. Ltd.
Changbaishan Pharmaceutical Co. Ltd. (Changbaishan)
Chiatai Tianqing Pharmaceutical Group Co. Ltd.
Cspc Pharmaceutical Group Ltd.
Elekta Instrument Ab Stockholm
Fsens
Guangzhou Aic Biotechnologies Ltd
Guangzhou Anchordx Llc
Guangzhou Ezlife Bio Inc.
Guangzhou Forever Gen Bio-Technology Ltd.
Guizhou Yibai Pharmaceutical Co. Ltd. (Yibai)
Guoda Drugstore
Hainan Zhonghe Pharmaceutical Co. Ltd.
Hansoh
Hitachi Medical
Huadong Medicine Co. Ltd.
Huapont Life Sciences Co. Ltd.
Hybio Pharmaceutical Co. Ltd.
Jiangsu Hengrui Medicine Co. Ltd. (Hengrui)
Livzon Pharmaceutical Group Co. Ltd. (Livzon)
Lunan Pharmaceutical Group
Luye Pharma Group (Luye)
Masep Infini Medical Science Technology Co. Ltd.
Msd China
Novartis
Pfizer China
Qilu Pharmaceutical Co. Ltd.
Roche China
Sanofi
Sciclone Pharmaceuticals Inc.
Shanghai Bioasia Gene Co. Ltd.
Shenzhen Haplox Biotechnology Co. Ltd.
Shenzhen Yucebio Co. Ltd.
Sinopharm A-Think Pharmaceutical Co. Ltd. (A-Think)
Sinopharm Chuankang Pharmaceutical Co. Ltd. (Chuankang)
Sl Pharm
Taiho Pharma
Varian Medical Systems Inc.
Wuhan Hualong Bio-Chemical Pharmaceutical Co. Ltd.
Yatai Pharmaceuticals
Zhejiang Jiuxu Pharmaceutical Co. Ltd. (Jiuxu)
Zhejiang Kanglaite Pharmaceutical Co. Ltd. (Kanglaite)
Zhendong Group
Continued…
Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2820088
Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)